RNA
Avidity Biosciences, Inc.
Key Financials
Revenue
$18.8M
↑ 72.1%
EPS (Diluted)
$-4.97
↓ 72.0%
Net Income
$-684631000
↓ 112.4%
Total Assets
$2.0B
↑ 25.2%
Operating Income
$-745943000
↓ 96.9%
Total Liabilities
$269.4M
↑ 93.9%
Shareholders' Equity
$1.7B
↑ 18.5%
Cash & Equivalents
$382.5M
↑ 74.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 15-12G | 3/9/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RNA |
| Company Name | Avidity Biosciences, Inc. |
| CIK | 1599901 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-401-7900 |